ResearcherSheng Jing HospitalNo recent work listed

Mu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9871-7488; OpenAlex author ID A5100399457. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers

Papers 3

The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2020.117936 ↗
The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells. Co-author DOI 10.21037/atm-20-5880 ↗
Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy. Co-author DOI 10.1002/cbin.10760 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shaowei Song · 3 shared papers, 2017–2020 · strength 0.33
Xiaodong Tan · 2 shared papers, 2020 · strength 0.25
- Paper The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cell… DOI 10.21037/atm-20-5880 ↗
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Jing Ye · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Yuhong Li · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Yang Ge · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Xingda Wu · 1 shared paper, 2017 · strength 0.08
- Paper Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy. DOI 10.1002/cbin.10760 ↗
Fanbin Meng · 1 shared paper, 2017 · strength 0.08
- Paper Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy. DOI 10.1002/cbin.10760 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.